Another complication arises from the fact that the drug's manufacturer has not registered it in the Czech Republic, impeding negotiations on pricing. Barbora Dubanská, a specialist in health law, points out that the final cost of CZK 100 million may be subject to adjustment due to potential negotiations and risk-sharing contracts with insurance companies.